Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GRK2 | P25098 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.48 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 5/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6609835 | 0.90 | POLB (0.48) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6610841 | 0.90 | KEAP1 (0.48) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6610937 | 0.89 | POLB (0.48) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6608669 | 0.89 | KMT2A (0.48) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL5656436 | 0.89 | LMNA (0.48) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6611811 | 0.88 | KDM4E (0.48) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6608209 | 0.88 | KEAP1 (0.47) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6613405 | 0.87 | KEAP1 (0.44) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6614500 | 0.86 | KMT2A (0.52) | POLBGRK2PPARGKMT2ACTDSP1 | |
| SCHEMBL6607925 | 0.86 | POLB (0.50) | POLBGRK2PPARGKMT2ACTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
| US-6544984-B1 | Treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss. | AMERICAN CYANAMID COMPANY | 2003-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | MMP12, MMP1, SI | POLB 2255/4885GRK2 3303/4885PPARG 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.